|Assessment Status||Assessment Process Complete|
|Indication||For the prevention of stroke in atrial fibrillation.|
|Rapid review commissioned||17/08/2011|
|Rapid review completed||31/08/2011|
|Rapid review outcome||Full Pharmacoeconomic Evaluation Recommended|
|Full submission received from Applicant||11/11/2021|
|NCPE assessment completed||02/04/2012|
|NCPE assessment outcome||Reimbursement not Recommended|
The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.
Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012). At this revised price we now consider rivaroxaban cost effective for this indication. A positive recommendation was made on the 19/06/2012.